Polycystic ovay syndrome Nutritional, Metabolic, Endocrine Polycystic ovarian syndrome
Conditions
Interventions
All subjects will be asked to arrive fasting in the morning. Informed consent will be taken. Blood, saliva, sebum and urine samples will be collected during the follicular phase of menstrual cycle if
Sponsors
Hull and East Yorkshire Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. PCOS subjects as per Rotterdam criteria 2. Age 18 to? 40 years Inclusion criteria - controls 1. Aged 18 to 40 years 2. Regular menstrual cycles 21 to? 35 days 3. No clinical or biochemical evidence of hyperandrogenemia 4. Normal thyroid-stimulating hormone (TSH) and prolactin 5. No first degree relatives having polycystic ovary syndrome
Exclusion criteria
Exclusion criteria: 1. Non-classical 21-hydroxylase deficiency 2. Hyperprolactinaemia 3. Cushing?'s disease 4. Androgen-secreting tumours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular risk will be assessed by lipid profile, high-sensitivity C-reactive protein (hsCRP), 75g oral glucose tolerance test, HOMA and endo PAT | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Genetic polymorphism: DNA samples will be extracted and studied for genetic polymorphisms 2. Hormonal parameters including free androgen index, Dehydroepiandrosterone sulfate (DHEAS), androstenedione and 17OH progesterone will be measured 3. Quality of life will be assessed using questionnaires including PCOS QoL questionnaire | — |
Countries
United Kingdom
Outcome results
None listed